Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational multimodal analgesic regimen developed by **Inova Health Care Services** for the management of postoperative pain, specifically in patients undergoing coronary artery bypass graft (CABG) surgery. The regimen consists of oral **gabapentin**, which modulates the alpha-2-delta subunit of voltage-gated calcium channels to inhibit the release of excitatory neurotransmitters, and intravenous **acetaminophen**, which provides analgesia through the inhibition of prostaglandin synthesis in the central nervous system. This combination is being evaluated as an opioid-sparing approach (the **INOVAOPIOID** study) to reduce the incidence of opioid-related adverse events, such as postoperative ileus and respiratory complications, while providing effective pain relief compared to standard opioid-based protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + acetaminophen.